Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
Intrinsic Value
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. [ Read More ]
The intrinsic value of one
DCPH
stock under the Base Case scenario is
25.15
USD.
Compared to the current market price of 14.58 USD,
Deciphera Pharmaceuticals Inc
is
Undervalued by 42%.
DCPH's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
DCPH or that its price is influenced by factors unrelated to fundamentals.
Deciphera Pharmaceuticals Inc's market capitalization is 1.2B USD.
DCPH stock price is 14.58 USD.
DCPH stock price (14.58 USD) is 42% less than its Intrinsic Value (25.15 USD).
DCPH. Open DCF Valuation
DCPH stock price (14.58 USD) is 42% less than its Relative Value (25.15 USD). Open Relative Valuation
DCPH has upside potential of 69% compared to the average analyst price target.
Open Wall St Estimates
DCPH's Revenue has grown by an exceptional 22% over the past 12 months.
DCPH's ROE (Return on Equity) has significantly decreased in the last 3 years from -43% to -56%, and is approaching profitability.
DCPH's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -463% to -168%, and is approaching profitability.
DCPH's Revenue is forecast to grow at a rate of 32% per year over the next 3 years.
DCPH has negative Operating Income for the last twelve months.
DCPH has negative Net Income for the last twelve months.
DCPH's ROE (Return on Equity) for the past 12 months is negative and is equal to -56%.
DCPH's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -168%.
DCPH has positive Gross Profit for the last twelve months.
DCPH's Revenue has been growing by an exceptional 57% per year for the last 3 years.
DCPH has negative Free Cash Flow for the last twelve months.
DCPH's Altman Z-Score is very low and is equal to 0.94.
DCPH's short-term assets (381m USD) exceed its short-term liabilties (100m USD).
DCPH's long-term assets (474m USD) exceed its long-term liabilties (123m USD).
DCPH has negative three-year average ROE (Return on Equity): -56%. The company is not efficient at transforming stockholders' equity into net income.
DCPH has negative three-year average ROIC (Return on Invested Capital): -254%. The company is not efficient at using invested capital to generate operating income.
DCPH's D/E (Debt to Equity) is very low and is equal to 0.
Valuation Backtest
Deciphera Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
DCPH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Deciphera Pharmaceuticals Inc
Balance Sheet Decomposition
Deciphera Pharmaceuticals Inc
| Current Assets | 381.1m |
| Cash & Short-Term Investments | 306.2m |
| Receivables | 32m |
| Other Current Assets | 42.9m |
| Non-Current Assets | 92.5m |
| Long-Term Investments | 46.7m |
| PP&E | 37.5m |
| Other Non-Current Assets | 8.3m |
| Current Liabilities | 100.3m |
| Accounts Payable | 26.5m |
| Accrued Liabilities | 47.7m |
| Other Current Liabilities | 26.1m |
| Non-Current Liabilities | 22.4m |
| Other Non-Current Liabilities | 22.4m |
Earnings Waterfall
Deciphera Pharmaceuticals Inc
|
Revenue
|
163.4m
USD
|
|
Cost of Revenue
|
-3.7m
USD
|
|
Gross Profit
|
159.6m
USD
|
|
Operating Expenses
|
-370.6m
USD
|
|
Operating Income
|
-211m
USD
|
|
Other Expenses
|
16m
USD
|
|
Net Income
|
-194.9m
USD
|
Free Cash Flow Analysis
Deciphera Pharmaceuticals Inc
What is Free Cash Flow?
DCPH Profitability Score
Profitability Due Diligence
Deciphera Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Deciphera Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
DCPH Solvency Score
Solvency Due Diligence
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DCPH Price Targets Summary
Deciphera Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
DCPH
is 24.68 USD
with a low forecast of 9.09 USD and a high forecast of 35.7 USD.
Ownership
DCPH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DCPH Price
Deciphera Pharmaceuticals Inc
| Average Annual Return | 22.33% |
| Standard Deviation of Annual Returns | 87.19% |
| Max Drawdown | -90% |
| Market Capitalization | 1.2B USD |
| Shares Outstanding | 80 800 096 |
| Percentage of Shares Shorted | 9.99% |
Company Profile
Deciphera Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 280 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The company has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.
Contact
IPO
Employees
Officers
The intrinsic value of one
DCPH
stock under the Base Case scenario is
25.15
USD.
Compared to the current market price of 14.58 USD,
Deciphera Pharmaceuticals Inc
is
Undervalued by 42%.
You don't have any saved screeners yet
